New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying

  New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about
                   Burdening Family and Friends Than Dying

-- As men live longer with disease, survey findings suggest patients and
caregivers need increased opportunities for open dialogue and more
comprehensive support --

PR Newswire

NORTHBROOK, Ill. and SAN FRANCISCO, Sept. 26, 2013

NORTHBROOK, Ill. and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Astellas
Pharma US, Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today
announced results of a national survey of men with advanced prostate cancer
and caregivers of men with advanced prostate cancer.[i] Results showed that
while patients who participated in the survey are generally optimistic, a good
number may feel isolated in coping with their disease. Forty-five percent
reported they keep silent about their prostate cancer and treatments, and 59
percent are concerned about becoming a burden to family and friends. By
comparison, only 43 percent of patient respondents have the same level of
concern about dying.

Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of
Illness Survey

Caregivers who participated in the survey expressed a high degree of stress
associated with their roles. Nearly three-quarters (73 percent) said there are
days when they feel overwhelmed caring for someone with advanced prostate
cancer and 85 percent said they experience stress or anxiety related to their
loved one's well-being. However, caregiver respondents are more concerned
about helping their loved one cope with the physical and emotional effects of
advanced disease (83 percent) than they are about their own physical or
emotional health (58 percent).

Astellas Pharma US, Inc. and Medivation, Inc. commissioned the Advanced
Prostate Cancer Patient and Caregiver Burden of Illness Survey through Harris
Interactive, and sponsored four leading cancer advocacy and education
organizations to collaborate on the initiative: The Association of Oncology
Social Work (AOSW), CancerCare, Prostate Health Education Network (PHEN), and
Us TOO Prostate Cancer Education and Support Network. The survey was conducted
online among 91 men with advanced prostate cancer and 100 caregivers of such
men, and was designed to evaluate the physical and emotional impact of
advanced prostate cancer on both patients and caregivers.

"Little, if any, research has been completed to understand the current
experience of U.S. men living with advanced prostate cancer or caregivers to
these men," said Thomas A. Farrington, founder and president of PHEN. "This
survey provides much-needed information that will help us better support them,
particularly as there is evidence that men are now living longer with advanced
disease."

More than 50 percent of patients who participated in the survey have been
living with a prostate cancer diagnosis for at least six years. Nearly
one-third of survey respondents (33 percent) reported living with a diagnosis
for more than 10 years and 17 percent said they are currently living with
another cancer diagnosis in addition to prostate cancer.

Caregiver respondents reported an average caregiving duration of nearly five
years. Sixteen percent have been providing care for more than eight years.

Key findings from patients who participated in the survey reveal:

  oForty-one percent do not feel like people understand what they are going
    through in terms of managing and treating their prostate cancer. Of these,
    78 percent* wish people better understood the stress of coping with
    prostate cancer, and more than half wish others understood the
    inconvenience caused by prostate cancer (59 percent) or the side effects
    of treatment (also 59 percent).
  oWhile many patient respondents reported feeling hopeful about their
    disease (58 percent), the greatest percentage said their disease makes
    them feel uncertain (62 percent). Among other responses, 33 percent said
    they feel fearful, 32 percent feel sad, and 20 percent feel lonely or
    alone.
  oThere are disconnects in terms of patients' treatment priorities and what
    they perceive to be the priorities of their physicians. While 66 percent
    of patients said that the level of discomfort they will experience is
    important or very important to them when choosing therapies, only 45
    percent believe that this factor is important or very important to their
    physicians.
  oDespite the older age of patients who participated in the survey (median
    age: 70 years), the Internet is an important source of information for
    them. After their physicians, it is the most highly used source of
    information for patients and caregivers who participated in this survey.

Caregiver participants expressed considerable stress and anxiety, as well as a
desire for more direct support networks. Key findings include:

  oSeventy-three percent said they are concerned or very concerned about
    their ability to continue providing care over a long period of time.
  oCaregivers' top areas of concern are their ability to help their patient
    cope with the physical and emotional effects of the disease (83 percent
    said they are concerned/very concerned about each).
  oAmong the 93 percent of caregivers who reported experiencing troublesome
    feelings as a result of caregiving (e.g., stress, sadness, fear, etc.), 58
    percent said they rely most on family members to help relieve these
    feelings.
  oAmong caregivers who expressed a desire for additional support, the most
    common request was for a support network or group.

Survey findings also suggest that many patient and caregiver respondents are
overwhelmed by the volume of information available to them. About one-third
(35 percent) of patients said there is too much information available about
prostate cancer to understand it all, and 47 percent of caregivers agreed with
this statement. These findings suggest the need for navigation tools that will
help guide patients and caregivers to the information that is most relevant to
them over the course of the disease.

The American Cancer Society estimates that one in six U.S. men will be
diagnosed with prostate cancer in their lifetime and about 2.5 million are
currently living with the disease.[ii]^, Recent studies and analyses have
demonstrated that men with advanced prostate cancer are now living longer than
ever.[iii],[iv] A 2013 study concluded, "The initial impact of treatments for
men with [prostate cancer] is well reported in the literature. Less is known
about the psychosocial needs of these men as their journey after diagnosis and
treatment continues into months and years."[v]

About the Advanced Prostate Cancer Patient and Caregiver Burden of Illness
Survey
The Advanced Prostate Cancer Patient and Caregiver Burden of Illness Study was
conducted online within the United States by Harris Interactive on behalf of
Astellas Pharma US, Inc. and Medivation, Inc. between August 29, 2012 and
March 15, 2013. A total of 91 men age 60+ diagnosed with prostate cancer who
have been or are being treated with at least one course of hormone therapy and
experienced continued disease progression (i.e., castration-resistant prostate
cancer [CRPC]) completed the survey. Simultaneously, Harris Interactive
surveyed 100 caregivers of similarly described patients, defined as anyone in
regular contact with qualified patients who assist with their care and/or help
them make treatment decisions.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients and
their caregivers. For more information, please visit us at www.medivation.com.

About Astellas
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a US affiliate
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceutical products. The organization
is committed to becoming a global category leader in focused areas by
combining outstanding R&D and marketing capabilities. For more information
about Astellas Pharma US, Inc., please visit our website at www.Astellas.us.

[i] For the purposes of this survey "advanced" disease was defined as prostate cancer
that has been or is are being treated with at least one course of hormone therapy and has
continued to progress (i.e., castration-resistant prostate cancer [CRPC]). "Caregivers"
was defined as anyone in regular contact with qualified patients who assist with their
care and/or help them make treatment decisions.
[ii] American Cancer Society. What are the key statistics about prostate cancer?
Available at
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics.
Accessed August 5, 2013.
[iii] Omlin, A. et. al. Improved Survival in a Cohort of Trial Participants with
Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated
Prognostic Nomograms. Euro Uro. 64:2. August 2013
[iv] Mukherji, D. et. al. New treatment developments applied to elderly patients with
advanced prostate cancer. Can Trtmnt Rev. 39:578-573. 2013.
[v] O'Shaughnessy, PK, et. al. Cancer Nurs. 2013 Jan 25.
* Caution:  Small base size; results should only be interpreted as directional in nature.



Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of
Illness Survey



Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of
Illness Survey



Astellas Pharma US, Inc. Logo



Medivation, Inc. Logo



PDF available at:
http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/FX-MM86689-SURVEY-FACT-SHEET.pdf

Image with caption: "Findings from The Advanced Prostate Cancer Patient and
Caregiver Burden of Illness Survey." Image available at:
http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-a

Image with caption: "Findings from The Advanced Prostate Cancer Patient and
Caregiver Burden of Illness Survey." Image available at:
http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-b

Image with caption: "Findings from The Advanced Prostate Cancer Patient and
Caregiver Burden of Illness Survey." Image available at:
http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-c

Image with caption: "Astellas Pharma US, Inc. Logo." Image available at:
http://photos.prnewswire.com/prnh/20130926/MM86689LOGO-d

Image with caption: "Medivation, Inc. Logo." Image available at:
http://photos.prnewswire.com/prnh/20130926/MM86689LOGO-e

SOURCE Medivation, Inc.; Astellas Pharma US, Inc.

Contact: Medivation Contacts: Patrick Machado, Chief Business & Financial
Officer, (415) 829-4101, Anne Bowdidge, Senior Director, Investor Relations,
(650) 218-6900; Astellas Contacts: Jenny Kite, Corporate Communications, (847)
682-4530; Mike Beyer, Sam Brown, Inc (media for both companies), (773)
463-4211